Advanced Solid Tumor
Conditions
Interventions
Experimental Group:Gallium [68Ga]-Nectin-4 Bicyclic Peptide Injection Combined with PET/CT Imaging
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years (inclusive), regardless of gender; 2.Pathologically confirmed solid tumors with high Nectin-4 expression (e.g., urothelial carcinoma, breast cancer, lung cancer, etc.); 3.At least one assessable tumor lesion (primary or metastatic); 4.Voluntary signed informed consent and ability to cooperate with the study procedures. 5.ECOG performance status 0 to 2, with an expected survival of >=6 months;
Exclusion criteria
Exclusion criteria: 1. Combined with other active malignancies (except non-melanoma skin cancer or carcinoma in situ); 2. Severe cardiac, hepatic, and renal insufficiency (such as ALT/AST > 3 times ULN, creatinine clearance < 30 mL/min); 3. Uncontrolled systemic infection or immune system disease; 4. Pregnant or lactating females, or patients of childbearing age who do not take effective contraceptive measures; 5. Prior Nectin-4 targeted therapy (e.g., enfortumab vedotin).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events;Serious adverse events; | — |
Secondary
| Measure | Time frame |
|---|---|
| Biological distribution characteristics;Targeting Ability for Solid Tumors with High Nectin-4 Expression; | — |
Countries
China
Contacts
Public ContactDeng Shengming
The First Affiliated Hospital of Soochow University
Outcome results
None listed